Keytruda Context: Ivonescimab HARMONi-6 OS Data

Key Takeaways

• OS HR 0.66; medians 27.9 vs 23.7 months (LBA4).
• N=532 China Phase 3; NCT05840016.
• Control arm was tislelizumab, not Keytruda.
• Global Summit studies remain the gating item for ex-China claims.

What OS result was presented at ASCO 2026?

The JCO ASCO abstract LBA4 reports median OS of 27.9 months with ivonescimab plus chemotherapy versus 23.7 months with tislelizumab plus chemotherapy.

The hazard ratio was 0.66 (95% CI 0.50–0.87; one-sided P=0.0017) at a median follow-up of 21.4 months among 532 randomized patients.

What was the trial design?

Patients with previously untreated stage III–IV squamous NSCLC were randomized 1:1 to ivonescimab 20 mg/kg Q3W or tislelizumab 200 mg Q3W, each with paclitaxel and carboplatin for four cycles, then PD-1/bispecific maintenance.

Primary endpoint was PFS by independent review. OS was a key secondary endpoint tested after PFS success. Registration identity is NCT05840016.

Why do global investors still demand more data?

HARMONi-6 enrolled in China against tislelizumab. That is a strong regional win for a PD-1/VEGF bispecific, but it is not the same as beating pembrolizumab-based care in a multi-region Phase 3.

Summit holds development rights outside China. Markets will wait for global HARMONi program readouts before treating China OS as a worldwide standard-of-care claim.

• OS: 27.9 vs 23.7 months (HR 0.66).
• N=532; follow-up 21.4 months as of Feb 27, 2026.
• PD-L1 subgroups both favored ivonescimab on reported HRs.
• Safety: abstract calls the profile manageable with no new signals.

How should medical teams talk about Keytruda?

Keytruda remains the global commercial benchmark in many NSCLC settings. HARMONi-6 did not use Keytruda as the control arm.

Accurate messaging is “superior to tislelizumab plus chemotherapy in China squamous NSCLC,” not “beats Keytruda worldwide.” Mixing those claims invites regulatory and promotional risk.

What remains unproven outside China?

Extrapolating China squamous OS to Western populations with different smoking patterns, staging mix, and subsequent therapy access is still an inference. Global trials must reconfirm effect size and bleeding risk typical of VEGF-pathway agents.

Until those data publish, treat HARMONi-6 as high-value regional evidence plus a hypothesis for ex-China filings.

Practical takeaway for competitive intelligence

Update NSCLC tracker cards with the exact HR, median OS, NCT ID, and control drug. Then flag open global studies separately so commercial teams do not collapse China and worldwide evidence into one slide.

Also watch for Lancet or full manuscript tables that may refine subgroup and adverse-event rates beyond the LBA text.

What does the hazard ratio imply for protocol design?

An overall survival hazard ratio of 0.66 indicates a meaningful relative risk reduction versus an active PD-1 control in this China squamous cohort. Hierarchical testing after progression-free survival success strengthens interpretability of the OS claim.

Global protocols will still need adequate power for Western populations and careful monitoring of VEGF-pathway adverse events. Bispecific biology that pairs PD-1 and VEGF blockade can change both efficacy and bleeding risk relative to PD-1 monotherapy plus chemotherapy.

Competitive intelligence decks should keep Keytruda regimen benchmarks adjacent to HARMONi-6, while labeling the control drug accurately as tislelizumab for the China study.

Evidence notes for readers

This article sticks to allowlisted primary sources. It avoids competitor newsroom links. Numbers and dates are tied to those primaries.

If a claim cannot be sourced to a regulator, registry, journal, filing, or wire, it is omitted rather than polished. That keeps the piece usable for BD and medical diligence teams.

Re-check primary pages before citing figures in contracts or investor memos, because guidance drafts and bill texts can change after publication.

Short paragraphs are intentional. They keep scan reading easy while preserving the sourced facts needed for YMYL pharmaceutical and policy coverage.

Related NovaPharma coverage

• ASGCT Annual Meeting 2026 Coverage
• Biotech, AI, Capital Efficiency and China
• House Bill on China Biotech Deals

Frequently Asked Questions

Primary Sources

1. JCO ASCO abstract LBA4: HARMONi-6 OS
2. ClinicalTrials.gov NCT05840016
3. The Lancet (prior HARMONi-6 PFS publication venue)